DK3795167T3 - Pd-1-peptidinhibitorer - Google Patents
Pd-1-peptidinhibitorer Download PDFInfo
- Publication number
- DK3795167T3 DK3795167T3 DK20204314.7T DK20204314T DK3795167T3 DK 3795167 T3 DK3795167 T3 DK 3795167T3 DK 20204314 T DK20204314 T DK 20204314T DK 3795167 T3 DK3795167 T3 DK 3795167T3
- Authority
- DK
- Denmark
- Prior art keywords
- peptide inhibitors
- peptide
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395195P | 2016-09-15 | 2016-09-15 | |
| EP17778394.1A EP3512536B1 (en) | 2016-09-15 | 2017-09-15 | Pd-1 peptide inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3795167T3 true DK3795167T3 (da) | 2022-08-29 |
Family
ID=60009711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20204314.7T DK3795167T3 (da) | 2016-09-15 | 2017-09-15 | Pd-1-peptidinhibitorer |
| DK17778394.1T DK3512536T3 (da) | 2016-09-15 | 2017-09-15 | Pd-1-peptidinhibitorer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17778394.1T DK3512536T3 (da) | 2016-09-15 | 2017-09-15 | Pd-1-peptidinhibitorer |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10098950B2 (da) |
| EP (2) | EP3512536B1 (da) |
| JP (1) | JP6928083B2 (da) |
| AU (1) | AU2017325866B2 (da) |
| CA (1) | CA3036251A1 (da) |
| DK (2) | DK3795167T3 (da) |
| WO (1) | WO2018053218A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3036251A1 (en) | 2016-09-15 | 2018-03-22 | Leidos, Inc. | Pd-1 peptide inhibitors |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| WO2019168524A1 (en) * | 2018-02-27 | 2019-09-06 | Leidos, Inc. | Pd-1 peptide inhibitors |
| CN111647064B (zh) * | 2018-10-30 | 2021-08-03 | 诺赛联合(北京)生物医学科技有限公司 | 一种改进的能与pd-1特异性结合的肿瘤抑制肽及其用途 |
| JP2023529839A (ja) | 2020-06-04 | 2023-07-12 | レイドス， インコーポレイテッド | 免疫調節性化合物 |
| EP4225444A1 (en) * | 2020-10-12 | 2023-08-16 | Leidos, Inc. | Immunomodulatory peptides |
| CN113336824A (zh) * | 2021-04-30 | 2021-09-03 | 重庆理工大学 | 一种多肽在作为pd-1/pd-l1蛋白-蛋白相互作用(ppi)调节剂中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002513811A (ja) | 1998-05-06 | 2002-05-14 | ファルマシア・アンド・アップジョン・カンパニー | 非−ヒト脊椎動物への、非−ヒト脊椎動物のペプチドホルモンまたはサイトカインをコードする裸のｄｎａまたは裸のｒｎａの導入 |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2012168944A1 (en) | 2011-06-08 | 2012-12-13 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| EP2822957A1 (en) | 2012-03-07 | 2015-01-14 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| CA2868408A1 (en) | 2012-03-29 | 2013-10-03 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
| ES2739913T3 (es) | 2013-02-22 | 2020-02-04 | Curevac Ag | Combinación de vacunación e inhibición de la ruta PD-1 |
| WO2016032927A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| CA3036251A1 (en) | 2016-09-15 | 2018-03-22 | Leidos, Inc. | Pd-1 peptide inhibitors |
| CN107383174B (zh) | 2017-08-21 | 2019-01-18 | 生工生物工程（上海）股份有限公司 | 一种能与pd-1特异性结合的肿瘤抑制肽及其用途 |
-
2017
- 2017-09-15 CA CA3036251A patent/CA3036251A1/en active Pending
- 2017-09-15 WO PCT/US2017/051697 patent/WO2018053218A1/en unknown
- 2017-09-15 JP JP2019515467A patent/JP6928083B2/ja active Active
- 2017-09-15 US US15/705,333 patent/US10098950B2/en active Active
- 2017-09-15 DK DK20204314.7T patent/DK3795167T3/da active
- 2017-09-15 EP EP17778394.1A patent/EP3512536B1/en active Active
- 2017-09-15 DK DK17778394.1T patent/DK3512536T3/da active
- 2017-09-15 EP EP20204314.7A patent/EP3795167B1/en active Active
- 2017-09-15 AU AU2017325866A patent/AU2017325866B2/en active Active
-
2018
- 2018-03-01 US US15/908,861 patent/US10799581B2/en active Active
-
2020
- 2020-09-21 US US17/026,447 patent/US20210000948A1/en not_active Abandoned
-
2023
- 2023-11-08 US US18/388,036 patent/US20240075131A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3512536T3 (da) | 2020-11-23 |
| JP2019531293A (ja) | 2019-10-31 |
| US20180185474A1 (en) | 2018-07-05 |
| AU2017325866A1 (en) | 2019-04-18 |
| US10799581B2 (en) | 2020-10-13 |
| US20210000948A1 (en) | 2021-01-07 |
| EP3795167A1 (en) | 2021-03-24 |
| EP3512536A1 (en) | 2019-07-24 |
| US20180071385A1 (en) | 2018-03-15 |
| JP6928083B2 (ja) | 2021-09-01 |
| US10098950B2 (en) | 2018-10-16 |
| CA3036251A1 (en) | 2018-03-22 |
| WO2018053218A1 (en) | 2018-03-22 |
| EP3795167B1 (en) | 2022-08-03 |
| US20240075131A1 (en) | 2024-03-07 |
| AU2017325866B2 (en) | 2021-09-09 |
| EP3512536B1 (en) | 2020-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3612525T3 (da) | Pd-1-/pd-l1-inhibitorer | |
| MA54543A (fr) | Inhibiteurs de kif18a | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| ES2969185T3 (es) | Inhibidores de RET | |
| DK3497086T3 (da) | Aminopyrimidin-SSAO-inhibitorer | |
| CL2016002502A1 (es) | Inhibidores de biaril cinasa | |
| MA44474A (fr) | Nouveaux inhibiteurs de la ferroportine | |
| CL2016002638A1 (es) | Nuevos inhibidores de la nitrificación | |
| CU20160125A7 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| DK3681884T3 (da) | Rad51-inhibitorer | |
| MA52812A (fr) | Inhibiteurs de sarm1 | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| DK3512536T3 (da) | Pd-1-peptidinhibitorer | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| DK3116475T3 (da) | Dopa-decarboxylasehæmmersammensætninger | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| DK3341379T3 (da) | EZH2-hæmmere | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
| DK3355890T3 (da) | Humane plasmakallikreininhibitorer | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| BR112016023299A2 (pt) | Composto tricíclico e inibidor de jak |